New Cholesterol Drug May Enhance Cancer Immunotherapy Effectiveness

Cancer patients undergoing immunotherapy often require additional medications to manage concurrent health conditions, most notably cholesterol-lowering drugs. While it was previously believed that these cholesterol medications had no impact on the progression of cancer treatment, a recent discovery has revealed surprising results.

Based on a data analysis of thousands of patient medical records, those using a new type of cholesterol medication were found to have longer life expectancies compared to patients using statins. Interestingly, this positive effect appears to be entirely unrelated to cardiovascular health.

This new generation of cholesterol medication is known as PCSK9 inhibitors. Their primary function is to assist the liver in clearing bad cholesterol from the bloodstream, typically used to reduce the risk of heart attacks and strokes in high-risk patients. A research team from the University of Texas Southwestern Medical Center (UT Southwestern) observed the effects of these drugs on cancer patients undergoing checkpoint inhibitor therapy—a type of immunotherapy designed to activate the immune system to attack tumours.

The results showed that patients also taking PCSK9 inhibitors survived significantly longer than those using statins. After two years of observation, approximately 62% of the PCSK9 inhibitor group remained alive, compared to only 51% in the statin group. The difference in median survival was even more striking: half of the PCSK9 inhibitor users survived up to approximately five years, whereas half of the statin users had passed away within about two years.

The research data was sourced from TriNetX, a network collecting anonymised medical records from over 70 healthcare systems in the United States. Researchers compared data from 239 patients using PCSK9 inhibitors with 239 patients using statins, matching them for characteristics such as age, cardiac history, and specific cancer types, including lung cancer, melanoma, and kidney cancer.

While the initial hypothesis was that the drug’s ability to prevent heart attacks and strokes might be extending lives, the data showed that the rates of serious cardiac events were equal in both groups. This suggests the survival benefit is independent of vascular health functions.

Laboratory evidence provides a clue to this phenomenon: the PCSK9 protein not only regulates cholesterol but also helps cancer cells hide from the immune system. When this protein is blocked by the medication, tumours may become easier for the immune system to detect and attack.

Despite the promise, this study, published in the journal JAMA Network ‘Network Open’, has only identified a pattern and cannot yet prove absolute causation. The analysed medical records still have limitations, such as missing data on tumour stages, immune markers, and confirmed causes of death.

Consequently, these findings have not yet changed current cancer treatment protocols. Doctors must wait for the results of ongoing clinical trials testing the direct effectiveness of combining PCSK9 inhibitors with immunotherapy in lung and kidney cancer patients. If these trials confirm the pattern, this breakthrough could be implemented rapidly, as PCSK9 inhibitors are already approved for use and have a long-standing safety record.